Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Sonora Investment Management Group LLC

Sonora Investment Management Group LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,802 shares of the biopharmaceutical company’s stock after selling 361 shares during the quarter. Sonora Investment Management Group LLC’s holdings in Gilead Sciences were worth $444,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $25,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Valued Wealth Advisors LLC raised its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Crews Bank & Trust purchased a new position in Gilead Sciences in the 4th quarter valued at $31,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 2nd quarter worth $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Robert W. Baird raised their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Wolfe Research assumed coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective on the stock. The Goldman Sachs Group raised their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ:GILD opened at $97.20 on Friday. The firm has a market capitalization of $121.14 billion, a PE ratio of 1,080.00, a price-to-earnings-growth ratio of 1.34 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm’s 50-day moving average is $92.28 and its two-hundred day moving average is $85.59.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.29 EPS. Analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.